This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a retrospectively cohort study that was carried out at several medical centres covered by the managed care plan. The patients were followed longitudinally post-index date to the discontinuation of index medication, the end of benefit eligibility, or to the end of the study period, whichever occurred first. All patients had a minimum of 4 months of post-index continuous eligibility. The average length of follow-up was 8.6 (+/-4.5) months. No patient appears to have been lost to the follow-up assessment.
Analysis of effectiveness
All of the patients included in the initial study sample were accounted for in the analysis of effectiveness. The outcome measures used were hypoglycaemia events, the absolute risk difference in hypoglycaemia events, and the numberneeded-to-treat (NNT) to avoid one hypoglycaemic event. A regression model was used to examine hypoglycaemia events, with the independent variable being insulin type (NPH or glargine). The covariates included a pre-index count of hypoglycaemia events, age, gender, best (lowest) post-index A1c (glycated haemoglobin), the use of regular insulin, and the use of oral hypoglycaemic agents. The model was run on the sub-cohort of patients who had post-index A1c measurements (n=875).
At baseline, the study groups were well balanced in their gender distribution, but statistically significant differences were observed in terms of: age (glargine patients were younger), co-morbidities (more NPH patients had hypertension, ischaemic heart disease, congestive heart failure and peripheral vascular disease), co-morbidity index (which was higher for NPH patients), Type 1 diabetes mellitus (more frequent among glargine patients), provider specialty, and payer type.
Effectiveness results
In the pre-index period, the number of patients with hypoglycaemic events was 20 (6.5%) in the glargine group and 47 (4.2%) in the NPH group. The number of events per cohort was 31 in the glargine group and 110 in the NPH group. Thus, the mean numbers of events per 100 patients per year were 30 (glargine group) and 29 (NPH group), respectively.
In the post-index period, the number of patients with hypoglycaemic events was 15 (4.8%) in the glargine group and 73 (6.5%) in the NPH group. The number of events per cohort was 22 in the glargine group and 258 in the NPH group. Thus, the mean numbers of events per 100 patients per year were 10 (glargine group) and 31 (NPH group), respectively.
The mean change from the pre-to the post-index in the number of events per 100 patients per year was -20 (95% confidence interval, CI: -3.2 --36.2) in the glargine group and 2 (95% CI: 20.7 --17.2) in the NPH group.
The model showed that the NPH group was over three times more likely than the glargine group to be associated with hypoglycaemic events (incident rate ratio 3.18, 95% CI: 1.33 -7.62).
The hypoglycaemia event rate per 100 patients per year was 7.3% in the glargine group and 18.3% in the NPH group, (p<0.05).
The absolute risk difference in hypoglycaemia events per 100 patients per year was 11 (0.11 per patient per year).
The NNT was 9. increase in cost associated with glargine treatment to prevent one hypoglycaemic event was lower than the cost of the event itself.
The base-case results were robust to changes investigated in the sensitivity analysis.
Synthesis of costs and benefits
A synthesis of the costs and benefits was not relevant since a cost-consequences analysis was performed.
Authors' conclusions
Patients initiated on glargine had a significantly lower hypoglycaemia event rate than those initiated on neutral protamine Hagedorn (NPH). Further, the increase in cost associated with switching patients from NPH to glargine was less than the mean attributable cost of one hypoglycaemic event.
CRD COMMENTARY -Selection of comparators
The authors justified the choice of the comparators, which were appropriate for the study question. You should decide whether they are valid comparators in your own setting.
Validity of estimate of measure of effectiveness
The effectiveness analysis came from a review of the data extracted from a large administrative database, where two cohorts of patients were compared. The use of a randomised and prospective design would have been more appropriate to limit the impact of selection bias and confounding. The study groups were not well balanced at baseline, thus a regression analysis was performed to adjust for such differences. However, the authors stated that no control for race or income was performed. The method used to select the sample of patients was reported and it appears that the patients have been followed for an appropriate period. No loss to follow-up was observed because only patients with complete charts were included in the analysis. The study sample was representative of the study population because individuals were selected from a large database. Further, the evidence came from multiple centres. The sample size was quite big, especially for the NPH group, although no justification was provided for the number of patients involved in the analysis.
Validity of estimate of measure of benefit
No summary benefit measure was used in the analysis because a cost-consequences analysis was conducted. Please refer to the comments in the 'Validity of estimate of measure of effectiveness' field (above).
Validity of estimate of costs
The analysis included costs consistent with the perspective adopted in the study, although it was restricted to the direct medical costs. A detailed breakdown of the cost items was not provided and the costs were presented as macrocategories. Thus, no information on the unit costs or quantities of resources used was provided. The cost data came from patient claims, and it was unclear whether charges rather than actual costs were used. The dates during which the resources used and costs were gathered were reported, although an explicit price year was not given. Statistical analyses of the costs were carried out, but the cost estimates were specific to the study setting. The authors noted that some insulin products were over-the-counter medications, thus it was difficult to assess them and include them in the cost analysis.
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